T alpha 1

New drug (Thymosin alpha 1) discovery: potential for Cystic Fibrosis treatment

According to an article published on www.sciencedaily.com, researchers have discovered a potential new drug to treat and stop the progression of cystic fibrosis. While many other promising drugs are in the pipeline, we here at cysticfibrosis.com will be keeping a keen eye on further developments of this medication. Read the …

READ MORE →
Indrepta C

Indrepta C Lottery Winners

Planetary Biosciences is holding a Give Away Lottery on the cysticfibrosis.com group, for 7 people receiving one bottle of Indrepta C, to celebrate the release of this new product.  If you want to be part of this lottery, please send an email to [email protected] with the Subject: Indrepta Lottery.  Please read …

READ MORE →
AbbVie

AbbVie scholarship for students with cystic fibrosis

Thanks to 25-years of medical advancement, the goal of pursuing higher education for many students with cystic fibrosis, an inherited chronic disease that affects the lungs and digestive system, is more achievable than ever before. AbbVie announced the opening of the application period for the AbbVie CF Scholarship program, marking …

READ MORE →
social media feature pic jan 2017

New on Cystic Fibrosis Social Media (@knowCF)

What’s new on the Cystic Fibrosis social media pages (@KnowCF)? We are active on social media – want to know the latest news? Please follow the links to see what is new on our Cystic Fibrosis Social Media channels. Post your own comment – or just see what others are …

READ MORE →
hard to treat Burkholderia cenocepacia

University of British Columbia studying B-cepacia with some success!

Burkholderia cenocepacia has been a very hard to treat bacterial infection for our Cystic Fibrosis  community.  Some of you may remember a member of our community, LightnLife…Lauren Beyenhoff.  She was a trained scientist and an active member of our site a few years ago. I remember our days on Second …

READ MORE →
hearing loss

Risk of Hearing Loss from IV Aminoglycosides in Cystic Fibrosis

Cumulative exposure to IV tobramycin and amikacin, which are critical for treating cystic fibrosis infections, increases the risk of hearing loss. A study, “The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis,” published last month in the Journal of Cystic Fibrosis discusses how IV tobramycin, …

READ MORE →
Indrepta C

Indrepta C now available for nonsense mutations

Sharktank Research Foundation releases Indrepta C; a nutritional supplement targeted for nonsense mutations Sharktank Research Foundation announces promising news for CF patients with ‘X’ or nonsense mutations, which cause a premature stop codon. The CFTR nonsense mutation W1282X is shown to be activated by a natural dietary supplement, curcumin.1 Recently, …

READ MORE →
concert pills

Treatment for Cystic Fibrosis: Vertex Acquires Concert’s CFTR Potentiator CTP-656

Vertex Pharmaceuticals recently purchased the Phase 2 cystic fibrosis potentiator drug CTP-656 from Concert Pharmaceuticals. The deal is estimated to be worth $250 million dollars. CTP-656 is intended to be a longer-acting, once daily version of Vertex’s drug ivacaftor, which aims to restore CFTR function in treatment for Cystic Fibrosis. …

READ MORE →
pollution chimney-324561_640

Respiratory Health and Air Pollution

The impact of small particle air pollution on the lower airways (lungs) has long been studied, but now scientists have evidence of its negative impact on the upper sinonasal airways as well. The World Health Organization’s recommendation for small particle air pollution (PM2.5) is that it not exceed an average …

READ MORE →
pseudomonas2

Does Ivacaftor Affect Lung Bacteria in Cystic Fibrosis?

Ivacaftor has been shown to increase CFTR activity and lung function in people with Cystic Fibrosis and the G551D mutation, but until a recent study, scientists were not sure if ivacaftor changed the level of bacteria in the lungs. The results of a deeper study on ivacaftor have been published, …

READ MORE →